Purpose The inflammatory response in injured brain parenchyma after traumatic brain injury (TBI) is crucial in the pathological process. In order to follow microglia activation and neuroinflammation after TBI, we performed PET imaging in a rat model of TBI using 
Introduction
Traumatic brain injury (TBI) is one of the leading causes of mortality and morbidity in people under the age of 45 years, and can result in temporal or long-term, even life-long, physical, cognitive and behavioral problems [1] . It causes structural damage and functional deficits due to both primary and secondary injuries. The primary injury is the mechanical disruption of brain tissue, and the secondary injury is the subsequent cascade of metabolic, cellular and molecular events, which is a result of biochemical derangements such as glutamate excitotoxicity, enhanced levels of free radicals, neuroinflammation and apoptosis [2] . Among the biochemical derangements, neuroinflammation is a key pathological response to brain injury and is characterized by glial cell activation including microglia and astrocytes, peripheral leukocyte and macrophage infiltration, and upregulation of proinflammatory mediators [3] . The inflammatory reaction after TBI is a double-edged sword and the detrimental effects of neuroinflammation on the injured brain have been well recognized [4] . However, it has also been clearly shown that beneficial effects can be achieved if neuroinflammation is controlled in a regulated manner and for defined periods of time [5] . Hence, accurate monitoring of the dynamics of neuroinflammation after TBI would be very helpful to design effective therapeutic interventions to avoid secondary injury.
As a primary safeguard in brain homogenesis, microglia undergo a shift in morphology as well as function once the brain is under pathological conditions including TBI [6] . Activated microglia are involved in tissue repair, amplification of inflammatory effects and neuronal degeneration, and the functional state of microglia may, to some extent, reflect the status of the immune reaction in the brain [5, 7] . Consequently, neuroinflammation in several models of central nervous diseases, such as brain tumor [8] , stroke [9] and Alzheimer's disease [10] , has been evaluated by PET using imaging probes targeting the 18-kDa translocator protein (TSPO). The reason for choosing TSPO as the microglial marker is that the majority of TSPO-positive cells in injured brain are microglia. Moreover, TSPO is expressed at low levels in healthy brain but is remarkably upregulated in response to injury and inflammation [11] .
Several TSPO ligands labeled with radioisotopes have been used for autoradiography or in vivo PET of neuroinflammation [12] [13] [14] [15] . Compared with other radioligands of TSPO, [ 18 F]DPA-714 has the advantage of high binding affinity and target-to-background ratio [16, 17] . Moreover, the half-life of 18 F (t 1/2 109.8 min) make it highly suitable for in vivo PET imaging. A pilot clinical study in healthy humans confirmed the in vivo stability and biodistribution, and acceptable effective dose estimation of [ 18 F]DPA-714, supporting further clinical trials and preclinical evaluation with this PET imaging radioligand [18] .
Therefore, we performed a longitudinal imaging study using [
18 F]DPA-714 for noninvasive real-time evaluation of neuroinflammation in a rat model of TBI. We also performed MRI and [ 18 F]FDG PET to monitor the anatomical and metabolic changes at the injury sites. These imaging studies were expected to provide a better understanding of the inflammation process after TBI and a useful in vivo monitoring method for antiinflammation therapy of TBI. 
Materials and methods

General materials
Animal model of traumatic brain injury
All animal studies were conducted in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals [19] and were approved by the Institutional Animal Care and Use Committee of the Clinical Center (National Institutes of Health).
TBI was induced in adult male Sprague-Dawley rats (body weight 300 -400 g) by a controlled cortical impact. Briefly, rats were anesthetized in a ventilated chamber by isoflurane (3.5 % for induction and 2 % for maintenance) and then placed in a stereotaxic device. A warm pad was used to keep the animal's body temperature at 37°C during surgery. After drilling a hole on the left area of the skull (2.8 mm left of and 3.2 mm back from the bregma), a rounded impact tip with a diameter of 5 mm was used to contuse the exposed dura mater. The tip penetration depth was 3.0 mm and the velocity was 5 m/s. Following the controlled cortical impact, the burr hole was covered with bone flap, sealed with Jet Denture Repair Professional Package (Lang Dental Manufacturing Co., IL). Sham-treated control rats were treated similarly but without activating the impactor.
Magnetic resonance imaging
All MRI scans were performed on a 7.0-T small-animal scanner (PharmaScan; Bruker) with a body coil. Rats were anesthetized by isoflurane and kept warm by a circulating water pad. T 2 -weighted images were obtained using a RARE sequence. The parameters were as follows: TR 3,000 ms, effective TE 70 ms, number of excitations 4, matrix size 256×256, field of view 4×4 cm, slice thickness 1 mm. The total acquisition time was approximately 8 min for each rat.
Positron emission tomography and data analysis ]DPA-714 displacement study, a 1-h dynamic acquisition was performed on rats on day 6 after TBI (three animals) with 5 mg/kg unlabeled PK11195 (mixture of R-PK11195 and R,S-PK11195, catalog no. AG-CR1-0008; Adipogen, San Diego, CA) administered via a tail vein 30 min after tracer injection. All images were reconstructed using a two-dimensional ordered-subsets expectation maximization algorithm. No scatter or attenuation correction was performed during image reconstruction.
Images were analyzed with an Inveon Research Workplace (Siemens). With fused PET/MRI images for guidance, threedimensional ellipsoidal regions of interest (ROIs) were manually defined on lesions in the ipsilateral hemisphere. Another ROI with the same shape was drawn on the corresponding region in the contralateral brain sphere as the normal background signal.
2,3,5-Triphenyl-2H-tetrazolium chloride staining
Slices of 1-mm thickness adjacent to those used for autoradiography were obtained for 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) staining as previously described [20] . All slices were stained with 2 % TTC solution and placed in the dark for 20 min at 37°C.
Ex vivo autoradiography
Ex vivo autoradiography was performed on days 2, 6, 10 and 20 after TBI (three animals for each time point). Around 25.9 MBq (700 μCi) of [
18 F]DPA-714 was administered under anesthesia to each rat via a tail vein. The rats were killed 1 h after injection and the brains were carefully removed. Axial sections of thickness 1 mm were obtained for autoradiography. The tissue slices were exposed to a high-efficiency storage phosphor screen overnight and developed in a Cyclone Plus storage phosphor system (PerkinElmer, Waltham, MA). The autoradiographs were analyzed with Optiquant acquisition and analysis software 5.0 (Perkin Elmer). With TTC-stained slices as reference, all autoradiographs were scaled with the same minimum and maximum thresholds to optimize visualization of the lesion sites. Then ROIs were outlined over the lesion sites on PET images of the ipsilateral sphere for quantification. Corresponding ROIs drawn on the contralateral normal brain tissue were used to determine lesion-to-normal brain ratios.
Immunofluorescence staining
Brain cryosections with a thickness of 8 μm were obtained using a Ultrapro 5000 cryostat (Vibratome, St. Louis, MO). All the sections were fixed with Z-fix solution for 15 min, and then nonspecific binding sites were blocked with PBS containing 1 % bovine serum albumin for 30 min. Slices were incubated with primary antibodies at 4°C overnight and then with secondary antibodies at room temperature for another 60 min. After each step, slices were washed gently three times with PBS containing 0.05 % Tween 20 for 5 min. For different staining targets, the antibodies and concentrations were as follows: rabbit anti-rat PBR (TSPO) antibody (1:50, sc-20120; Santa Cruz), mouse anti-rat CD68 antibody (1:100, ab955; Abcam) and goat anti-rat GFAP antibody (1:100, ab53554; Abcam); Cy3-conjugated donkey anti-rabbit secondary antibody (1:200; Jackson ImmunoResearch Laboratories), Dylight 488-conjugated donkey anti-rabbit secondary antibody (1:200; Jackson ImmunoResearch Laboratories) and Cy3-conjugated donkey anti-goat secondary antibody (1:200, Jackson ImmunoResearch Laboratories). All tissue slices were mounted with medium containing 4′,6-diamidino-2-phenylindole (DAPI), and then viewed in an epifluorescence microscope (X81; Olympus).
Statistical analysis
All data are expressed as means±standard deviation (means± SD). Statistical analysis was performed with SPSS software (version 18.0; SPSS, Inc., Chicago, IL). One-way analysis of variance (ANOVA) was used for data comparison between different groups and Student's t test was used for comparison of two groups. A p value <0.05 was considered statistically significant.
Results
Metabolic changes in the brain
From day 1 after surgery, a localized region with high signal intensity was observed in the cortex area on coronal T 2 -weighted MR images of the brain. This region was consistent with the site of TBI within several days. Therefore, T 2 -weighted MR images provided an anatomic reference for PET images (Fig. 1a) . In order to evaluate the glucose metabolism of injured brain, [ ]DPA-714 as imaging probe was performed to evaluate the dynamics of TSPO expression in brain parenchyma after TBI. Beginning on day 2 after surgery, increased tracer accumulation was observed over the injury site which reached a very high level on day 6. The signal intensity then decreased gradually with time. On day 28, no apparent localized tracer uptake was observed (Fig. 2a) .
[
18 F]DPA-714 uptake at different time points after TBI is shown in Fig. 2b . The lesion-to-normal brain ratio of tracer uptake was 1.68±0.15 on day 2, which was significantly higher than in the sham-treated group (1.02±0.08; p<0.01). The [ 18 F]DPA-714 uptake in the injury region peaked on day 6 with a ratio of 2.65±0.36 (p<0.001). The tracer uptake ratio then continued to decrease but was still significantly higher than in sham-treated rats on day 10 and day 16 (2.17±0.17 and 1.70±0.75, respectively; p<0.01). On day 28 after TBI, the ratio had reduced to 1.33±0.15, which was slightly higher than in sham-treated rats but without a significant difference (p>0.05). The change in uptake ratio of [ In order to further confirm the specific binding of [ 18 F]DPA-714 to TSPO in brain tissue, a dynamic displacement study was performed using unlabeled PK11195 in TBI rats on day 6 after surgery (Fig. 3) . The uptake of [ 714 in the injured brain area reached a plateau in several minutes after injection in both groups. After injection of PK11195, the tracer uptake in the lesion region dropped quickly to a plateau at a much lower level. A slight decrease in [ 18 F]DPA-714 uptake was also seen in normal brain tissue but to a much lesser extent than that in the lesion region. As shown in Fig. 3b , before displacement, apparent localized tracer accumulation was observed in the injured brain site. After PK11195 displacement, the signal intensity dropped dramatically, indicating the binding specificity of [ The uptake ratio increased from day 2, with the highest ratio on day 6, and then decreased gradually over several days (Fig. 4b) .
Immunohistological staining
To further evaluate TSPO expression in traumatically injured brain tissues, we performed immunofluorescence staining of tissue sections acquired at different time points after surgery. The staining results demonstrated a time-course of TSPO expression similar those shown by both in vivo PET and ex vivo autoradiography. The peak TSPO expression appeared on day 6 after TBI as indicated by a strong red fluorescence signal (Figs. 5 and 6) .
In order to delineate the cell source of TSPO overexpression, we costained brain tissue sections with either CD68 (Fig. 5) or GFAP (Fig. 6) . Compared with normal brain tissue, a few CD68-positive cells appeared from day 2 within lesion sites. On day 6, the injured areas were full of CD68-positive cells with an amoeba shape, which were morphologically identified as activated microglia. There were still many visually smaller CD68-positive cells in the damaged brain tissue on days 10 and 16. At early stage (from day 2 to day 6) after surgery, most of the fluorescence signal from TSPO and CD68 staining coincided, indicating that TSPO expression is mainly from activated microglia in injured brain. In late stages, especially on day 16 after surgery, only partial coincidence of the signal was observed (Fig. 5) . As shown in Fig. 6 , GFAPpositive cells appeared on day 10 after surgery and coincided with TSPO-positive cells, indicating that localized astrocytes may also contribute to the expression of TSPO.
Discussion
As a promising marker of neuroinflammation, TSPO is highly expressed in activated microglia. The low-level expression of TSPO in normal brain tissue provides sufficient contrast to reveal the area of inflammation. Therefore, [
18 F]DPA-714 has been used for PET imaging of neuroinflammation in different models [9, 17, 21] . However, to the best of our knowledge, no application of this particular tracer in a model of TBI has been reported. In this study, we used [ As the dominant PET imaging tracer, [
18 F]FDG has also been used to evaluate cerebral glucose metabolism in rodent models of CNS disease [13, 22, 23] . Consistent with the findings of these studies, we found a low-uptake area in the early phase after damage due to disturbance of blood circulation and normal brain function. It is well established that localized microglia and infiltrated peripheral immune cells show elevated glycolysis after activation due to the oxidative burst [24] . Consequently, we observed a high signal intensity from the disarranged brain parenchyma on [ 18 F]FDG brain maps on day 5 and day 9. On day 15 after surgery, there was no significant difference in the [ 18 F]FDG uptake ratio between the TBI group and the sham-treated group. This was likely due to a combination of reduced inflammatory response and selfrecovery of brain tissue, as shown by the immunofluorescence staining results with GFAP, an astrocyte cell maker [25] . However, the time-course of [ 18 F]FDG uptake did not agree with a previous report of a lower metabolic ratio even on day 7 after injury [13] . This discrepancy could be explained by the use of different TBI models which may result in different levels of injury severity and inflammatory response patterns. Furthermore, Sprague-Dawley rats were used in this study, while Wistar rats were used in the previous study [13] . Differences between the rat strains might also partially account for the discrepancy [26] .
PET imaging using other TSPO ligands such as [ 11 C]PK11195 [12] and [ 18 F]FE-DAA1106 [13] have demonstrated the feasibility of this approach for observing the inflammatory changes after traumatic injury. In vitro autoradiography using [ 3 H]PK11195 showed a significant increase in TSPO expression after TBI from day 3 and lasting at least 14 days [15] . In vivo PET imaging using [ 11 C]PK11195 showed increased binding in TBI rats on day 10 after surgery [12] . However, the imaging contrast is not ideal, which may be due to the short physical half-life of findings [27] . There may be several explanations for this phenomenon, such as the existence of different subtypes of TSPO [27] or non-identical binding sites for DPA-714 and PK11195 [29] . It could also be induced by nonspecific leakage and retention of [ 18 F]DPA-714 due to edema and bloodbrain barrier disruption after TBI [30] .
Due to its excellent anatomical resolution, T 2 -weighted MRI was performed for lesion confirmation and guidance for PET quantification. It is still very challenging to outline PET ROIs based on fused PET/MR images due to the use of separate scanning systems. We are confident that the PET results did reflect the trend in changes of TSPO level over time as the results were consistent with the ex vivo autoradiography data.
Increased [
18 F]DPA-714 accumulation also correlated well with increased TSPO levels shown by immunofluorescence staining (Figs. 5 and 6 ). Tissue sections were costained with CD68-specific antibody which showed only a few CD68-positive cells in the injured foci on day 2 and greatly increased numbers on day 6 and day 10. It has been reported that resident activated microglia comprise the main cell type contributing to the elevated TSPO expression in damaged brain parenchyma [31] . A study using chimeric green fluorescent protein-expressing mice has shown that resident activated microglia comprise the predominant cell type in the acute and subacute phases after stroke [32] . Therefore, it is reasonable to establish a causal correlation between microglia activation and quantitative analysis of PET images using [ 18 F]DPA-714 as the imaging probe. However, it has been also reported that peripheral macrophages and reactive astrocytes can also express TSPO in different profiles [33, 34] . Indeed, GFAP-positive astrocytes were observed in injured brain tissue after day 10, and these cells also showed TSPO overexpression. Based on these results, we speculate that increased PET signal in the early stage is more related to activated microglia. In late stages, increased [ 18 F]DPA-714 uptake at the lesion site resulted from TSPO overexpression of microglia and other neuroinflammation-related cells. Further investigation is needed to fully delineate the contributions of different cell types to the outcome of PET.
Conclusion
In this study, we successfully visualized the neuroinflammation reaction induced by TBI in a rat model using [ time-course of TSPO overexpression from activated microglia and astrocytes in a real-time and noninvasive manner. The use of this method would facilitate a better understanding of the inflammation process after TBI, and provide a useful in vivo monitoring strategy for antiinflammation therapy of TBI.
